<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439868</url>
  </required_header>
  <id_info>
    <org_study_id>WXL108709</org_study_id>
    <nct_id>NCT00439868</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure</brief_title>
  <official_title>A Cross-over Study to Evaluate the Effect of WELLBUTRIN XL on Intraocular Pressure in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in healthy volunteers to investigate the effect on intraocular
      pressure of 2 weeks of treatment with 300mg WELLBUTRIN XL/day.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2007</start_date>
  <completion_date type="Actual">June 8, 2007</completion_date>
  <primary_completion_date type="Actual">June 8, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure at Day -1, Days 1 &amp; 14.</measure>
    <time_frame>at Day -1, Days 1 &amp; 14.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure,Pupil diameter, anterior chamber angle</measure>
    <time_frame>Days-1,1&amp;14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wellbutrin XL plasma level</measure>
    <time_frame>Days1,12-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lab tests,ECG,vital signs:</measure>
    <time_frame>screening,followup</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lab tests:</measure>
    <time_frame>Days-2,13-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG:</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs:</measure>
    <time_frame>Days-2,-1,1,14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Period 1 of treatment group 1 will receive oral doses of extended release WELLBUTRIN XL tablets for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD. In Period 2 subject will receive placebo for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Period 1 of Treatment group 2 will receive Placebo for 2 weeks and in Period 2 subject will receive oral doses of extended release WELLBUTRIN XL for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WellbutrinXL</intervention_name>
    <description>WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.</description>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_label>Treatment Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Matching placebo tablets to WELLBUTRIN XL.</description>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_label>Treatment Group 2</arm_group_label>
    <other_name>WellbutrinXL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females.

          -  Non-smokers

          -  Agree to remain in the clinic for the time defined in the protocol.

          -  Normal ECG.

        Exclusion Criteria:

          -  Any serious medical disorder or condition.

          -  Any history of an endocrine disorder.

          -  Any clinically significant laboratory abnormality.

          -  History of psychiatric illness.

          -  Any history of suicidal attempts or behavior.

          -  Risk factors for precipitation of angle closure glaucoma or elevated IOP.

          -  Inability to refrain from use of contact lenses during the study days, if correction
             is required.

          -  Self-administered Beck Depression Inventory II scale total score greater than 9, and a
             suicide question score of greater than zero.

          -  Current or past history of seizure disorder or brain injury (traumatic or
             disease-related); or any condition which, in the opinion of the investigator,
             predisposes to seizure - Women having a positive serum HCG pregnancy test at
             screening, a positive urine pregnancy test before admission to the Unit during the
             in-house periods, who are not willing to use acceptable methods of contraception or
             who are lactating or planning to become pregnant within the three months following the
             screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/WXL108709?search=study&amp;search_terms=WXL108709#rs</url>
    <description>Results for study WXL108709 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2007</study_first_submitted>
  <study_first_submitted_qc>February 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2007</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>WELLBUTRIN XL, intraocular pressure, healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

